Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05936489 · ClinicalTrials.gov registry record · Phase 1
Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
A Phase 1 study, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05936489 is a Phase 1 study that has completed, run by LENZ Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT05936489, a Phase 1 study, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.
Interventions
- DRUG Aceclidine
- DRUG Aceclidine + Brimonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2023-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05936489
The ClinicalTrials.gov registry entry for NCT05936489 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LENZ Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aceclidine is the first listed.
NCT05936489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05936489 about?
NCT05936489 is a clinical study titled "Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia". This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.
What is the current status of trial NCT05936489?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-06. Estimated completion is 2023-10-03.
What interventions are being tested in trial NCT05936489?
The interventions under investigation include: Aceclidine (DRUG), Aceclidine + Brimonidine (DRUG).
Who is sponsoring clinical trial NCT05936489?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.